Patient Preferences for Attributes of Advanced Migraine Prevention Medications: Findings from a Discrete Choice Experiment

Todd J. Schwedt,Ashley Martin,Steven Kymes, Brian Talon,Xin Ying Lee,Roger Cady,Divya Asher,Meghana Karnik-Henry,Emily Mulvihill,Dawn Bates,Kathleen Beusterien

HEADACHE（2023）

引用 0|浏览5

暂无评分

摘要

Anti-CGRP monoclonal antibodies and onabotulinumtoxinA have demonstrated efficacy and tolerability, the two most important migraine treatment attributes. This study assessed the relative importance of other attributes in the choice of preventive migraine treatment from the patient perspective.

查看译文

关键词

advanced migraine prevention medications,patient preferences,choice

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要